Benchmark Maintains Buy on Quipt Home Medical, Lowers Price Target to $9
Portfolio Pulse from Benzinga Newsdesk
Benchmark analyst Bill Sutherland maintains a Buy rating on Quipt Home Medical (NASDAQ:QIPT) but lowers the price target from $10 to $9.
May 20, 2024 | 12:58 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Benchmark analyst Bill Sutherland maintains a Buy rating on Quipt Home Medical but lowers the price target from $10 to $9.
The Buy rating suggests continued confidence in the company's performance, but the lowered price target indicates a more cautious outlook on its short-term valuation.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100